MONDAY, April 8, 2024 (HealthDay News) — New research questions the effectiveness of the U.S. Food and Drug Administration’s accelerated drug approval program after finding that many cancer drugs remain unproven five years later. The study, published Sunday in the Journal of the American Medical Association and presented simultaneously atContinue Reading